This kind of comparison helps illustrate the general shape of the research, but it is not designed to help someone choose a level independently
CrossRef Diversity in metabolic dysfunction-associated steatotic liver disease: a framework for precision medicine Donghyun Ko, Jordan Low, Peter Low, Damien Chua, Yock Young Dan, Vincent Chen, Jonathan A
These are worst during the first 1-2 weeks at each new dose and usually improve
GIP activation enhances insulin sensitivity and contributes to fat metabolism
It increases the risk for multiple metabolic complications including type 2 diabetes (T2D), metabolic-dysfunction associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease), cardiovascular disease as well as many mechanical complications such as osteoarthritis and obstructive sleep apnoea (OSA) [3]
Antioxidants (Basel)